GAMMA Investing’s Taysha Gene Therapies TSHA Stock Holding History

GAMMA Investing’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.83K	Buy	786 +554	+239%	+$3.19K	﹤0.01%	3759
2026 Q2	$1.58K	Buy	232 +97	+72%	+$574	﹤0.01%	3770
2026 Q1	$603	Sell	135 -141	-51%	-$656	﹤0.01%	3919
2025 Q4	$1.52K	Buy	+276	New	+$1.34K	﹤0.01%	3684

Other funds holding TSHA

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Williams & Novak Westlake Village, California $169M AUM 17.63% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GAMMA Investing's TSHA Position: Q3 2026 in Review

GAMMA Investing increased its Taysha Gene Therapies (TSHA) stake by 239% in Q3 2026, buying an estimated $3.19K and bringing the position to 786 shares worth $3.83K. The position accounts for ﹤0.01% of the portfolio, ranked #3759.

GAMMA Investing first reported a position in TSHA in Q4 2025 and has held it in 4 quarters since. 7 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

GAMMA Investing held 786 shares of Taysha Gene Therapies worth $3.83K as of Q3 2026.
GAMMA Investing bought 554 Taysha Gene Therapies shares in Q3 2026, an estimated $3.19K.
Taysha Gene Therapies made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3759 holding.
GAMMA Investing first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 4 quarters since.
7 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.